Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2175 results found since Jan 2013.
Higher Buprenorphine Dose May Improve Treatment Retention for Opioid Use Disorder
Patients who received a higher daily dose of buprenorphine (24 mg) were significantly more likely to remain in treatment over six months compared with those who received a lower dose (16 mg), according to astudy published this week inJAMA Network Open.“The U.S. Food and Drug Administration recommends a target dose of 16 mg for buprenorphine maintenance treatment, with an upper limit of 24 mg,” wrote Laura Chambers, Ph.D., M.P.H., of Brown University and colleagues. The authors noted that this recommendation was established prior to the emerge nce of fentanyl in the illicit drug supply. “Some physicians have suggested...
Source: Psychiatr News - September 21, 2023 Category: Psychiatry Tags: buprenorphine discontinuation fentanyl JAMA Network Open Nora Volkow opioid use disorder Rhode Island treatment retention Source Type: research
Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy
Diabetes Metab J. 2023 Sep 6. doi: 10.4093/dmj.2023.0018. Online ahead of print.ABSTRACTDiabetic peripheral neuropathy (DPN) is one of the most prevalent chronic complications of diabetes. The lifetime prevalence of DPN is thought to be >50%, and 15%-25% of patients with diabetes experience neuropathic pain, referred to as "painful DPN." Appropriate treatment of painful DPN is important because this pain contributes to a poor quality of life by causing sleep disturbance, anxiety, and depression. The basic principle for the management of painful DPN is to control hyperglycemia and other modifiable risk factors, but these...
Source: Diabetes and Metabolism Journal - September 6, 2023 Category: Endocrinology Authors: Han Na Jang Tae Jung Oh Source Type: research
Tapee Tea contains hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use Tapee Tea, a product promoted and sold for pain relief on www.tapeeteausa.com, www.tapeetea.com, and possibly in some retail stores.
Source: FDA Center for Drug Evaluation and Research - What's New - August 31, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Bach1 inhibitor HPP-D mediates γ-globin gene activation in sickle erythroid progenitors
Blood Cells Mol Dis. 2023 Aug 17;104:102792. doi: 10.1016/j.bcmd.2023.102792. Online ahead of print.ABSTRACTSickle cell disease (SCD) is the most common β-hemoglobinopathy caused by various mutations in the adult β-globin gene resulting in sickle hemoglobin production, chronic hemolytic anemia, pain, and progressive organ damage. The best therapeutic strategies to manage the clinical symptoms of SCD is the induction of fetal hemoglobin (HbF) using chemical agents. At present, among the Food and Drug Administration-approved drugs to treat SCD, hydroxyurea is the only one proven to induce HbF protein synthesis, however, it...
Source: Blood Cells, Molecules and Diseases - August 26, 2023 Category: Hematology Authors: Chithra D Palani Xingguo Zhu Manickam Alagar Otis C Attucks Betty S Pace Source Type: research
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
This article summarizes key aspects of the regulatory review, including the indication statement, efficacy and safety considerations, and postmarketing requirements.PMID:37624619 | DOI:10.1158/1078-0432.CCR-23-1272
Source: Clinical Cancer Research - August 25, 2023 Category: Cancer & Oncology Authors: Deepti Telaraja Yvette L Kasamon Justin S Collazo Ruby Leong Kun Wang Ping Li Elyes Dahmane Yuching Yang Justin Earp Manuela Grimstein Lisa R Rodriguez Marc R Theoret Nicole J Gormley Source Type: research
FDA Approval Summary: Dabrafenib in combination with trametinib for BRAF V600E mutation-positive low-grade glioma
Clin Cancer Res. 2023 Aug 23:CCR-23-1503. doi: 10.1158/1078-0432.CCR-23-1503. Online ahead of print.ABSTRACTOn March 16, 2023, the U.S. Food and Drug Administration (FDA) approved dabrafenib in combination with trametinib (Tafinlar®, Mekinist®, Novartis Pharmaceuticals Corporation) for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. FDA also approved oral formulations of both drugs suitable for patients who cannot swallow pills. This approval was based on the LGG cohort from Study CDRB436G2201 (NCT02684058), a multicenter, open-label trial in which ...
Source: Clinical Cancer Research - August 23, 2023 Category: Cancer & Oncology Authors: Michael I Barbato Jeannette Nashed Diana Bradford Yi Ren Sachia Khasar Claudia P Miller Banu S Zolnik Hong Zhao Yangbing Li Youwei Bi Stacy S Shord Anup K Amatya Pallavi S Mishra-Kalyani Barbara Scepura Raniya A Al-Matari Richard Pazdur Paul G Kluetz Mart Source Type: research
